论文部分内容阅读
[目的]分析评价肺癌化疗患者临床路径实施效果。[方法]采用同期对照法,选取2013年1月1日至2013年12月31日在辽宁省肿瘤医院住院的254例肺癌化疗患者为研究对象,其中符合肺癌化疗临床路径纳入标准的201例患者为临床路径组,其他53例患者为非临床路径组。对比分析两组患者的平均住院日、费用构成比,分析肺癌化疗患者的入径率、入径完成率。[结果]临床路径组平均住院日小于非临床路径组,约有56%的患者平均住院日达到标准住院日要求,临床路径组平均住院费用小于非临床路径组。肺癌化疗患者临床路径入径率79.13%,入径完成率89.1%。[结论]肺癌化疗患者临床路径管理可以有效缩短住院日、在一定程度上控制了住院费用的增长。
[Objective] To analyze and evaluate the clinical effect of chemotherapy in patients with lung cancer. [Methods] By using the method of synchronous control, 254 patients with lung cancer who were hospitalized in Liaoning Provincial Tumor Hospital from January 1, 2013 to December 31, 2013 were selected as the research subjects. Among them, 201 patients who met the clinical pathways of lung cancer chemotherapy For the clinical pathway group, the other 53 patients were non-clinical pathway groups. The average length of hospital stay and the cost of the two groups of patients were compared and analyzed, and the rate of entry into and completion of chemotherapy for lung cancer were analyzed. [Results] The average length of stay in the clinical pathway group was less than that in the non-clinical pathway group. About 56% of the patients had the average length of stay up to the standard hospitalization day. The mean hospitalization costs in the clinical pathway group were less than those in the non-clinical pathway group. The clinical pathology of patients with lung cancer chemotherapy was 79.13% and 89.1%, respectively. [Conclusion] The management of lung cancer patients with clinical pathways can effectively shorten the hospitalization days, to a certain extent, control the growth of hospitalization costs.